Robert Floyd Spectral Med Inc EDT-T WEAK BUY Jan 07, 2005

Will have to see a development of their Test kits (?) and have been slow in coming.

Robert Floyd

Owned

Unlock Rating

$1.100

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

A really neat little company. Good funding of their R&D. They have revenue and operating profits. Agreement with Cardinal will be good for getting tests done in US.

HOLD

Has been in the doldrums. They have to do a better job of marketing the company and letting investors know exactly what they're up to. Haven't had anything strong enough yet to move the company forward.

BUY

Likes.

COMMENT

There is nothing more powerful than a base breakout, and this had one in February of this year. This one is on a trend line right now and there is absolutely nothing wrong with the chart.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Robert Floyd Spectral Med Inc EDT-T WEAK BUY Jan 07, 2005

You might be interested:

Spectral Med Inc(EDT-T)

Spectral Med Inc(EDT-T)

Spectral Med Inc(EDT-T)

Spectral Med Inc(EDT-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights